Cognitive Assessment scale for Stroke Patients (CASP): a multicentric validation study - 21/10/21
, Grégoire Wauquiez 3, Dominic Pérennou, MD, PhD 4, 5, Céline Piscicelli, PhD 4, 5, Brigitte Lucas-Pineau, MD 6, Huei-Yune Bonnin-Koang, MD 7, Philippe Vuadens, MD 2, Christine Binquet, MD, PhD 8, Abderrahmane Bourredjem 8, Hervé Devilliers, MD, PhD 8Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Highlights |
• | The Cognitive Assessment scale for Stroke Patients (CASP) is a rapid test for screening for post-stroke cognitive impairment. |
• | It can be performed at the patient's bedside by a non-expert examiner. |
• | A CASP score of <35/36 should alert to the possible presence of cognitive impairment. |
• | The score can help predict a medium-term cognitive prognosis. |
Abstract |
Background |
The Mini Mental State Examination and Montreal Cognitive Assessment are commonly used as short screening batteries for assessing cognitive impairment after stroke. However, aphasia or hemispatial neglect may interfere with the results. For this reason, we developed the Cognitive Assessment scale for Stroke Patients (CASP), which takes these conditions into consideration and previously demonstrated its superiority over these scales in terms of feasibility.
Objectives |
Our goal was to verify the psychometric properties of the (original) French version of the CASP.
Methods |
We included 201 patients with a recent first hemispheric stroke and 50 controls. Stroke patients were examined 4 times (visit 1 [V1] to visit 4 [V4]) in the subacute post-stroke phase. The structural validity of the CASP was studied by principal factorial analysis, convergent validity by comparison with several variables including a comprehensive neuropsychological assessment, divergent validity by comparison with the total score between stroke patients and controls, and sub-scores between right and left stroke. Internal consistency, reproducibility and sensitivity to change were assessed. We propose the Minimal Clinically Important Difference (MCID) value and a pathological threshold as well as a threshold to predict cognitive change between V1 and V4.
Results |
Of the 201 participants included (63% male; mean [SD] age 63 [13] years), CASP data were available for 199/150/133/93 at V1/V2/V3/V4, respectively. CASP has a one-dimensional structure. The hypotheses of convergent/divergent validities were confirmed. Internal consistency was good and reliability excellent. Responsiveness was small to moderate, but the MCID could still be estimated. We discuss the choice of a pathological threshold and a predictive threshold of V1 over V4.
Conclusions |
CASP has good psychometric properties for screening cognitive impairment in the subacute post-stroke phase, which is consistent with its Italian and Korean versions. It can be used for patients with severe motor aphasia or left hemispatial neglect but not in case of severe oral comprehension or visual impairment.
Le texte complet de cet article est disponible en PDF.Keywords : Validation studies, Stroke, Cognitive, Assessment
Abbreviations : ASRS, AUC, BDAE, CASP, CFI, CNA, MCID, MMSE, MoCA, PFA, RMSEA, SEM, SRM, SRMR, TLI
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?